Literature DB >> 28523416

Utility of CT oral contrast administration in the emergency department of a quaternary oncology hospital: diagnostic implications, turnaround times, and assessment of ED physician ordering.

Corey T Jensen1, Katherine J Blair2, Ott Le2, Jia Sun3, Wei Wei3, Brinda Rao Korivi2, Ajaykumar C Morani2, Nicolaus A Wagner-Bartak2.   

Abstract

PURPOSE: To compare studies with and without oral contrast on performance of multidetector computed tomography (CT) and the order to CT examination turnaround time in cancer patients presenting to the emergency department (ED). To the best of our knowledge, oral contrast utility has not previously been specifically assessed in cancer patients presenting to the emergency department. MATERIALS &
METHODS: Retrospective review of CT abdomen examinations performed in oncology patients presenting to the emergency department during one month. CT examinations performed with and without oral contrast were rated by two consensus readers for degree of confidence and diagnostic ability. Correlations were assessed for primary cancer type, age, sex, chief complaint/examination indication, body mass index, intravenous contrast status, repeat CT examination within 4 weeks, and disposition. Turnaround times from order to the start of the CT examination were calculated.
RESULTS: The studied group consisted of 267 patients (127 men and 140 women) with a mean age of 56 years and a mean body mass index of 27.8 kg/m2. One hundred sixty CT examinations were performed without oral contrast, and 107 CT examinations were performed with oral contrast. There was no significant difference between cases with oral contrast and cases without oral contrast in the number of cases rated as "improved confidence" (odds ratio [OR] 0.54, 95% confidence interval [CI] 0.23-1.31, P = 0.17), "improved diagnosis" (OR 0.58, 95% CI 0.20-1.64, P = 0.3), "impaired confidence" (OR 3.92, 95% CI 0.46-33.06, P = 0.21), or "impaired diagnosis" (OR 2.63, 95% CI 0.29-23.89, P = 0.39). The turnaround time in the group receiving oral contrast (mean, 141 min; standard deviation, 49.8 min) was significantly longer than that in the group not receiving oral contrast (mean, 109.2 min; standard deviation, 64.8 min) with a mean difference of 31.8 min (P < 0.0001).
CONCLUSION: On the basis of our findings and prior studies, targeted rather than default use of oral contrast shows acceptable diagnostic ability in the emergency setting for oncology patients. Benefit from oral contrast use is suggested in scenarios such as suspected fistula/bowel leak/abscess, hypoattenuating peritoneal disease, prior bowel surgery such as gastric bypass, and the absence of intravenous contrast administration. Improvement through the use of targeted oral contrast administration also supports the emergency department need for prompt diagnosis and disposition.

Entities:  

Keywords:  Abdominal; Bowel; Emergency; Oral contrast; Turnaround time

Mesh:

Substances:

Year:  2017        PMID: 28523416      PMCID: PMC5641226          DOI: 10.1007/s00261-017-1175-7

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  23 in total

1.  Negative predictive value of intravenous contrast-enhanced CT of the abdomen for patients presenting to the emergency department with undifferentiated upper abdominal pain.

Authors:  Hyungjoo Ham; Matthew D F McInnes; Michael Woo; Sylvie Lemonde
Journal:  Emerg Radiol       Date:  2011-11-10

2.  Evaluation of bowel distention and bowel wall appearance by using neutral oral contrast agent for multi-detector row CT.

Authors:  Alec J Megibow; James S Babb; Elizabeth M Hecht; Jennie J Cho; Carmela Houston; Michael M Boruch; Archie B Williams
Journal:  Radiology       Date:  2005-11-17       Impact factor: 11.105

3.  Nontraumatic acute abdominal pain: unenhanced helical CT compared with three-view acute abdominal series.

Authors:  Andrew B MacKersie; Michael J Lane; Robert T Gerhardt; Harry A Claypool; Sean Keenan; Douglas S Katz; Jonathan E Tucker
Journal:  Radiology       Date:  2005-10       Impact factor: 11.105

4.  Positive and negative contrast agents in CT evaluation of the abdomen and pelvis.

Authors:  D J Hamlin; F A Burgener
Journal:  J Comput Tomogr       Date:  1981-06

5.  Oral contrast solution and computed tomography for blunt abdominal trauma: a randomized study.

Authors:  R E Stafford; M D McGonigal; J A Weigelt; T J Johnson
Journal:  Arch Surg       Date:  1999-06

6.  Oral contrast is not necessary in the evaluation of blunt abdominal trauma by computed tomography.

Authors:  T V Clancy; M W Ragozzino; D Ramshaw; M P Churchill; D L Covington; J G Maxwell
Journal:  Am J Surg       Date:  1993-12       Impact factor: 2.565

7.  Patient encounter time intervals in the evaluation of emergency department patients requiring abdominopelvic CT: oral contrast versus no contrast.

Authors:  Ly N Huynh; Bret F Coughlin; Jeannette Wolfe; Fidela Blank; Steve Y Lee; Howard A Smithline
Journal:  Emerg Radiol       Date:  2004-05-29

8.  Routine use of positive oral contrast material is not required for oncology patients undergoing follow-up multidetector CT.

Authors:  Sreemathi Harieaswar; Arumugam Rajesh; Yvette Griffin; Raman Tyagi; Bruno Morgan
Journal:  Radiology       Date:  2009-01       Impact factor: 11.105

9.  Accuracy of multidetector row computed tomography for the diagnosis of acute bowel ischemia in a non-selected study population.

Authors:  Walter Wiesner; Andreas Hauser; Wolfgang Steinbrich
Journal:  Eur Radiol       Date:  2004-09-17       Impact factor: 5.315

10.  Does high body mass index obviate the need for oral contrast in emergency department patients?

Authors:  Matthew L Harrison; Paul E Lizotte; Talmage M Holmes; Phillip J Kenney; Charles B Buckner; Hemendra R Shah
Journal:  West J Emerg Med       Date:  2013-11
View more
  1 in total

1.  Impact of low-kVp scan technique on oral contrast density at abdominopelvic CT.

Authors:  Douglas H Sheafor; Mark D Kovacs; Philip Burchett; Melissa M Picard; Brenton Davis; Andrew D Hardie
Journal:  Radiol Med       Date:  2018-08-06       Impact factor: 3.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.